federal_register: 2021-05323
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts | regulation_id_numbers |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-05323 | Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability; Reopening of the Comment Period | Notice | The Food and Drug Administration (FDA or Agency) is reopening the comment period for the notice entitled "Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability" that appeared in the Federal Register of December 9, 2020. The Agency is taking this action to allow interested persons additional time to submit comments. | 2021-03-16 | 2021 | 3 | https://www.federalregister.gov/documents/2021/03/16/2021-05323/best-practices-in-developing-proprietary-names-for-human-nonprescription-drug-products-draft | https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05323.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA or Agency) is reopening the comment period for the notice entitled "Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry; Availability" that appeared... |